2Lee C, Cockett A, Cussenot K, et al. Proceedings of the Fifth International Consultation on Benign Prostatic Hyperplasia. United Kingdom: Health Publications Ltd, 2001:79 - 106.
3Chute CG, Panser LA, Girman CJ, et al. The prevalence of prostatism: a population based survey of urinary symptoms. J Urol, 1993, 150:85-89.
5Oesterling JE. Benign p rostatic hyperp lasia. Its natural history, ep idemiologic characteristics, and surgical treatment . Arch Faro Med, 1992,1:257 - 266.
6Narayan P, MP OLeary,G Davidai,et al. Early efficacy of tamsulosin versus terazosin in the treatment of men with benign prostatic hyper- plasia: a randomized, open-label trial. J Appl Res, 2005, 5(1) : 237 - 245.
7Suzuki Y, Katoh T, Isurugi K, et al. The efficacy and safety of terazosin and tamsulosin in patients with urinary disturbance accompanying prostatic hypertrophy. Hinyokika Kiyo, 2001,47( 1 ) : 15 -21.
8Okada H, Kamidono S, Yoshioka T, et al. A comparative study of terazosin and tamsulosin for symptomatic benign prostatic hyperplasia in Japanese patients. BJU Int, 2000, 85(6) : 676 -681.
9Na YJ, Guo YL, Gu FL. Clinical comparison of selective and non - selective alpha 1 A - adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group. J Med, 1998, 29(5 -6) : 289 -304.
10Lee E, Lee C. Clinical comparison of selective and non - selective alpha 1 A- adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses. BrJ Urol, 1997 Oct, 80(4): 606-611.
